(Date:12/3/2009)... , NEW DELHI, India, Dec. 3 /PRNewswire-Asi...Officer at Shenzhen Beike Biotechnology Co. Ltd.,(...ence on High-Risk Diabetic,Foot Care in New Delhi,...g,stem cell research and regenerative medicine com...Indian Podiatry Association (IPA), aimed,to help p...
(Date:12/2/2009)..., NEW YORK, Dec. 2 Reportlinker.... available in its catalogue: ,, Neurostimulati...w.reportlinker.com/p0164232/Neurostimulation---A-G...urostimulation market stands enthused by the growi...e in age-related diseases such as, Parkinson,s, an...
(Date:12/2/2009)...EW YORK, Dec. 2 Nearly ...y makers, and funders today convened to explore no...strategies at the inaugural Partnering for Cures ...ed center of the Milken Institute, convened Partn...orations needed to turn a scientific discovery int...
(Date:12/2/2009)..., CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Onco...) (TSX:ONC; NASDAQ: ONCY ) announced today that in...ering, the underwriters have exercised in full the...al 637,500 units. Each unit is comprised of one co...ant, and was sold at a price of US$3.00 per unit. ...
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4... for Neurological Diseases and,Disorders, OLDSMAR...International,Inc. (OTC Bulletin Board: CCEL) ("Cr... most established family cord blood banks, today a...elopment agreement with Saneron CCEL,Therapeutics,...estone in,efforts to develop promising regenerativ...
...E PARK, N.C., Jan. 29 ,Merial Limited and Chimerix...reement under which Merial will screen a Chimerix ...er the terms of this agreement, Merial has an,opti...identified for,possible animal health use., "This...pportunity to,further expand our ability to identi...
... end; no equity financings expected in 2008, - Si...ams to continue in,2008; latest data for all progr...Expansion of research and development investment i... targets beyond lysosomal diseases in 2008, CRANB...FOLD ), a biopharmaceutical company developing sma...
Other Biology Technology:Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 2Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 3Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 4Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14UCB Basophil Chip-IHC from 3H Biomedical AB
UCB CD4 T Cell Chip-IHC from 3H Biomedical AB
EPC Cell Chip-IHC from 3H Biomedical AB
MoDC Cell Chip-IHC from 3H Biomedical AB
Biology Products: